Addressing the Root Causes of Antimicrobial Resistance2025-12-11T16:01:21-05:00

Addressing the Root Causes of Antimicrobial Resistance

Antimicrobial resistance is projected to kill up to 10 million people a year by 2050.

We won’t let this happen.

TAXIS Pharmaceuticals is developing investigational therapies to combat antimicrobial resistance – we’re addressing the root causes of the issue and targeting the very foundation of bacterial survival. Our approach goes beyond traditional methods – we’re dismantling the cellular infrastructure, breaking down barriers, and disrupting the mechanisms that fuel antimicrobial resistance.

At TAXIS Pharmaceuticals, we envision a world where antimicrobial resistance is a thing of the past.

Our Investigational Therapeutics

TXA709 – FtsZ Inhibitors

Target bacterial cell division protein.

TXA709, our lead oral anti-MRSA agent, completed Phase I trials with no serious adverse events.

It has been shown to disrupt bacterial cell walls and holds potential for future development against Gram-negative bacteria. Designated a Qualified Infectious Disease Product (QIDP) by FDA.

Learn More

Efflux Pump Inhibitors (EPIs)

Aim to shut down bacterial defense mechanisms.

Our investigational EPIs aim to enhance existing antibiotics by inhibiting efflux pumps in multidrug-resistant bacteria like Pseudomonas aeruginosa, preventing the bacteria cells from flushing out antibiotics. We recently received a $2.67 million grant from the NIH to further our R&D for our first EPI candidate, aimed at combatting hospital-acquired pneumonia.

Learn More

Dihydrofolate Reductase Inhibitors (DHFRIs)

Target a crucial bacterial enzyme, hindering cell proliferation.

Focused on treating highly resistant gonorrhea, our investigational DHFRIs aim to disrupt the synthesis of essential materials for bacterial growth, providing a robust defense against future resistance.

Learn More

Our pipeline

Our pipeline

TAXIS is dedicated to eliminating the threat of antimicrobial resistance across a wide range of infectious diseases. We are currently researching new classes of anti-resistance agents that employ novel mechanisms of action.

Read about our PIPELINE

Read our latest news and insights

News Releases

TAXIS Pharmaceuticals Responds to CDC Report on Surge in Antibiotic-Resistant Bacteria

September 25, 2025 — TAXIS Pharmaceuticals today issued a statement in response to a new report from the Centers for Disease Control and Prevention (CDC), published in the Annals of Internal Medicine on September 23. The CDC report highlights a [...]

Read More

TAXIS Blog

How Innovation is Turning the Tide in the Costly Fight Against Antimicrobial Resistance

A century ago, antibiotics transformed medicine. What were once deadly infections suddenly became curable, ushering in an era where surgery, childbirth, and even everyday cuts carried far less risk. Unfortunately, that medical miracle is now under threat. Across the world, [...]

Read More

Media Coverage

Clinical Leader: The Rise Of Antimicrobial Resistance And Strategic Research Imperatives For 2026

By Gregory G. Mario, MBA, president and CEO, TAXIS Pharmaceuticals The ground beneath our feet is shifting. The foundational promise of modern medicine — that bacterial infections are a solvable problem – is being severely tested by an accelerating crisis: [...]

Read More

RECENT POSTS

PAGES

CONTACT US

TAXIS Pharmaceuticals, Inc.
9 Deerpark Dr.,
Monmouth Junction, NJ
08852, USA
t 732.230.3074

© 2025 TAXIS Pharmaceuticals, Inc.

Frank Pasqualone

Frank Carlo Pasqualone, MBA

Mr. Pasqualone brings decades of life sciences executive leadership experience to TAXIS. He is currently a Board Member of Enveric Biosciences, Inc., and serves as Chair of the Nominating and Governance Committee and Compensation Committee. Mr. Pasqualone spent eight years as Chief Business Officer of Theravance Biopharma, Inc., overseeing commercial operations for the company’s first marketed product and establishing the company’s worldwide external partnerships through Alliance Management. Previously, Mr. Pasqualone held executive leadership roles for 26 years at Bristol-Myers Squibb. His expertise includes international strategic oversight, executive P&L, major product launches, life cycle management, business development, exclusivity extensions, and drug development prioritization.

Mr. Pasqualone earned a bachelor’s degree in business administration from Bowling Green State University and an MBA from the University of Dayton.

Joe

Joe DePinto, MBA

Mr. DePinto is currently Head of Cells, Gene, and Advanced Therapies at McKesson Corporation. He spent the past 30 years focused on bringing life-saving specialty drugs to market, helping patients with complex diseases access advanced care, and developing healthcare industry leaders. Mr. DePinto’s experience includes global operations for multiple biotech, pharma, distribution, professional services, and technology companies. Prior to joining McKesson in 2022, he served as Chief Commercial Officer at Vineti, a technology start-up focused on industrializing the value chain for personalized therapies. DePinto has been published in multiple publications on cell and gene therapy, including Cell & Gene Therapy Insights and PharmaVoice.

Mr. DePinto earned a bachelor’s degree in marketing and an MBA with an emphasis on Pharmaceutical/Chemical Studies from Fairleigh Dickinson University.

Alan G.E. Wilson, PhD, Fellow ATS, FRSC

Alan G. E. Wilson, PhD, ATS, FRSC is currently Vice President of Drug Metabolism, Pharmacokinetics, and Toxicology and Pathology at Lexicon Pharmaceuticals, the Woodlands, Texas. He is internationally recognized in drug metabolism and pharmacokinetics and has over 30 years of experience working on product discovery and development for both small molecules and bio-therapeutics. His expertise is in the translation of early discovery data into the clinic with extensive experience in the conduct of pharmacokinetics in Phase 1-3 clinical studies and PK, PK/PD and population PK modeling. He has significant hands-on experience with the regulatory and GLP requirements for the conduct of ADME, PK and safety assessment studies to support regulatory submissions and clinical studies. He has contributed to, and led, successful IND, NDA and MAA submissions.

Prior to joining Lexicon, Dr. Wilson held senior management and leadership positions with major international pharmaceutical and life science companies (chemical, agricultural chemicals, pharmaceutical) including Monsanto, Searle, Pharmacia and Pfizer. He has been involved with the registration of a number of successful marketed products with experience in a number of therapeutic areas including cardiovascular, endocrinology (particularly diabetes), ophthalmology, arthritis, pain, NASH, and has extensive experience working with global regulatory agencies.

Dr. Wilson has Board of Director and Scientific Advisory experience with several companies.  He is Board Certified in Toxicology and has over 130 publications, including editorship of several books.  He has been an invited speaker and presenter at numerous domestic and international conferences.

Dr. Wilson received his Ph.D. in Drug Metabolism/PK from the University of Surrey, U.K. and his B.Sc. in Biochemistry from the University of Surrey, U.K.

Vincent H. Tam, Pharm.D., BCPS (Infectious Diseases)

Vincent H. Tam received a B.S. from the National University of Singapore, Singapore and his Pharm.D. from Albany College of Pharmacy in Albany, New York. He completed an infectious diseases pharmacy residency at Detroit Receiving Hospital in Detroit, Michigan and a clinical pharmacology / infectious diseases fellowship at Albany Medical College. He is currently a full Professor (tenured) at the University of Houston College of Pharmacy in Houston, Texas. He is board certified in pharmacotherapy with added qualifications in infectious diseases.

Dr. Tam is the (co-) author of over 140 peer-reviewed publications in antimicrobial pharmacokinetics / pharmacodynamics and infectious disease therapeutics. He is on the Editorial Boards of Antimicrobial Agents and Chemotherapy, and Journal of Global Antimicrobial Resistance. He has also served as a grant proposal reviewer for the National Institutes Health (NIH) and an ad hoc reviewer for more than 20 journals such as the Clinical Infectious Diseases, International Journal of Infectious Diseases, Journal of Antimicrobial Chemotherapy, Journal of Clinical Pharmacology, and Lancet Infectious Diseases.

Lynn Silver, Ph.D.

Dr. Silver’s expertise spans more than 30 years in the antibacterial discovery area. Her experience includes 21 years at Merck Research Laboratories where she conducted research and supervised groups involved in discovery efforts for new antibacterials in natural products and chemical collections, support of chemical synthetic projects on improved antibacterials, pre-clinical evaluation of antibacterial drug candidates and the study of antibacterial resistance. Dr. Silver has experience with many biotech start-ups, small and large pharmaceutical companies and venture capitalists in a variety of projects involving antibacterial discovery. Throughout her career, she authored significant research papers and reviews in the field of bacterial genetics, physiology, and biochemistry, as well as discovery and analysis of antibacterial agents. She is a member of ASM, the Editorial Board of Antimicrobial Agents and Chemotherapy, ASM Branch Lecturer, and is a member of several biotechnology company Scientific Advisory Boards.

Dr. Silver earned a doctorate at Tufts University in Molecular Biology and Microbiology and did her postdoctoral work on bacterial DNA replication at the Université de Genève, and on DNA replication biochemistry of bacteriophage T4 at the NIH.

Dean L. Shinabarger, Ph.D.

Dr. Shinabarger is CEO and owner of Micromyx, a microbiology services company located in Kalamazoo, Michigan. He received a B.S. in Biology in 1982 from Emporia State University and a Ph.D. in Microbiology from Louisiana State University in 1986. As a postdoctoral fellow in the laboratory of Dr. Leo Parks at North Carolina State University, Dr. Shinabarger studied sterol synthesis in yeast. In addition, he completed a second fellowship at the University of Illinois College of Medicine in Chicago under Dr. Chakrabarty, investigating Pseudomonas aeruginosa pathogenesis as related to cystic fibrosis patients’ lung infections. Dr. Shinabarger’s industrial career began in 1992 at Proctor & Gamble Pharmaceuticals in their anti-infective discovery program.

After 2 years, he moved to Upjohn Pharmaceuticals to join the discovery and development team working on the oxazolidinone class of antibacterial agents. Dr. Shinabarger played a major role in elucidating the mechanism of action/resistance to linezolid and represented Pharmacia during the FDA review and eventual approval of Zyvox in 2000. After Pfizer acquired Pharmacia in 2003, Dean exited the company and co-founded Micromyx, a microbiology services company that specializes in preclinical R&D for biotech, pharma, and animal health companies that are actively engaged in antibacterial and antifungal research.

Louis Donald Saravolatz, M.D., MACP

Dr. Saravolatz is recognized for his research in infectious disease, specifically in the areas of new drug therapies and rapid diagnostic microbiologic tests. He is currently Professor of Medicine and Chairman of the Department of Internal Medicine at St. John Hospital & Medical Center. The hospital is affiliated with Wayne State University School of Medicine, where he also serves as Director of Department of Medicine Molecular Biology Laboratory. Prior to his current role, he directed the infectious disease training program at Henry Ford Hospital for 14 years. Dr. Saravolatz has authored more than 400 articles, text book chapters, invited reviews and scientific presentations and serves as a member for over 16 professional societies, including The American College of Physicians, Infectious Disease Society of America and The American College of Epidemiology and the Royal Society of Medicine (London). He has received numerous honors and awards for his teaching ability and clinical expertise in infectious diseases and was made a Master of the American College of Physicians. In 2005, Dr. Saravolatz was awarded the academic achievement in medical management from the American College of Physicians Executive.

Dr. Saravolatz received his B.S from University of Michigan and earned his M.D from University of Michigan Medical School.

Daryl Patrick, DVM, Ph.D.

Dr. Patrick has been a specialist in nonclinical development for more than 30 years, starting at Merck where he ultimately served as Vice President/Head, Worldwide Safety Assessment, responsible for all nonclinical aspects of potential drug development candidates. He also served on Research and Development Management teams responsible for strategic R&D planning and oversight of drug development programs through approval. He then served as Vice President, Nonclinical Development at Vertex Pharmaceuticals, leading the establishment of disciplines in Toxicology and ADME to support early development efforts. At Vertex, Dr. Patrick then served on management oversight committees and was promoted to Vice President, Exploratory Development, responsible for all nonclinical development activities and Clinical Pharmacology. Since retiring from Vertex, Dr. Patrick has engaged in private consulting for biotechnology and life sciences companies focused on novel therapeutic targets. He serves on Scientific Advisory Boards and provides guidance on nonclinical development activities and engagement with regulatory agencies around the world. 
 
 
Dr. Patrick earned his DVM in Veterinary Medicine from Michigan State University and his Ph.D. in Veterinary Pathology from Iowa State University.

Marshall Morningstar, Ph.D.

Marshall Morningstar is a pharmaceutical veteran with 20 years of experience managing small-molecule discovery teams in small biotechnology and large pharmaceutical companies. He is currently consulting for Sage Therapeutics (Neuroscience), Nimbus Therapeutics (Oncology), and Flatley Discovery Labs (Cystic Fibrosis). He was previously Director of Medicinal Chemistry at the Broad Institute directing a portfolio of neglected disease efforts. Before joining Broad, he was the Head of Chemistry for collaborative discovery efforts for GVK BIO, directing multiple programs in metabolic disorders, pain, and oncology research. Prior to GVK Bio, he spent over 11 years in the AstraZeneca infection group.

Marshall received a bachelor’s degree in chemistry from the University of California, Berkeley and a doctorate in synthetic organic chemistry from MIT. 

David C. Hooper, M.D.

Dr. Hooper’s expertise is rooted in the molecular mechanisms of bacterial resistance to antimicrobial agents with a focus on quinolone resistance in Staphylococcus aureus and Escherichia coli. He previously served as President of the American Society for Microbiology, where he is currently the Meetings Board Chair. He is board certified in Internal Medicine and Infectious Disease, and Chief of the Infection Control Unit and Associate Chief and Fellowship Program Director of Division of Infectious Diseases at Massachusetts General Hospital.

Dr. Hooper received his B.A. in Microbiology from University of Texas at Austin. He earned his M.D. in Medicine from Washington University, and an Honorary M.A. from Harvard University.

David Kimball, Ph.D.

Dr. David Kimball joins TAXIS with more than 30 years of experience in the discovery and development of small molecule drug candidates. He currently serves as Associate Vice President for the Office of Research Commercialization (ORC) at Rutgers University. Dr. Kimball is also a Research Professor at the Ernest Mario School of Pharmacy.

Previously, Dr. Kimball was Chief Scientific Officer at Hydra Biosciences, a biopharmaceutical company focused on applying its understanding of Transient Receptor Potential (TRP) ion channels to the discovery of drugs for pain, inflammation and respiratory disease. He also served as Senior Vice President of Nonclinical Research at Pharmacopeia, Inc.

Dr. Kimball served as Vice President of Chemistry at Lexicon Pharmaceuticals, where he was responsible for building an organization of over 75 chemists, including medicinal, analytical, computational, process research and development, library synthesis and outsourcing chemistry. He spent the first 19 years of his career at Bristol-Myers Squibb Pharmaceutical Research Institute, most recently as Research Fellow in the Division of Medicinal Chemistry, Princeton, NJ.

Dr. Kimball earned his Ph.D. in Organic Chemistry/Chemical Biology from the State University of New York at Stony Brook.

Ernest Mario, Ph.D.

Dr. Mario currently serves as Chairman of Capnia and Chimerix, and is a Venture Partner with Pappas Ventures, a life science venture capital firm. In addition to his current and past service on several corporate boards, Dr. Mario is active in numerous educational and healthcare organizations. He is Chairman of the American Foundation for Pharmaceutical Education, a Director of the Gladstone Foundation, and past Chairman of the Duke University Health System. Dr. Mario served in management at a number of drug companies before being named in 1989 Chief Executive of Glaxo. During his tenure, Glaxo brought five major new products to market and saw sales and profits increase by 15% annually. Later Dr. Mario led drug delivery technology company Alza until selling it to Johnson & Johnson in 2001. He subsequently served as Chairman and CEO of Reliant Pharmaceuticals. Dr. Mario holds honorary doctorates from the University of Rhode Island and Rutgers University, the latter of which in 2001 renamed its pharmacy school the Ernest Mario School of Pharmacy. In 2007 he was awarded the Remington Medal by the American Pharmacists’ Association, pharmacy’s highest honor.

Dr. Mario received his B.S. in pharmacy from Rutgers University, and M.S. and Ph.D. in physical sciences from the University of Rhode Island.

  • TXA709, TAXIS’ lead product candidate, is a novel target – first-ever product to target FtsZ proteins.
  • Oral anti-MRSA agent that completed a Phase I clinical trial with no serious adverse events.
  • Ongoing research focuses on disrupting bacterial cell wall architecture to address drug resistance mechanisms.
  • TXA709 is developed as an anti-resistance drug for combination therapy with obsolete antibiotics.
  • Targets the FtsZ bacterial cell division protein, offering potential for future development against Gram-negative bacteria.
  • Designated a Qualified Infectious Disease Product (QIDP) by the FDA in September 2016.
  • Regulatory incentives include eligibility for Fast Track designation, priority review, and extended marketing exclusivity under the GAIN Act.
Ajit Parhi, Chief Scientific Officer

Ajit K. Parhi, PhD

Chief Scientific Officer

Dr. Parhi brings over 25 years of experience in the fields of organic chemistry, synthetic methodologies, natural product synthesis, medicinal chemistry, and drug discovery. Since the founding of TAXIS Pharmaceuticals, he has served as the Chief Medicinal Chemist and has led the company’s discovery research efforts since 2018. Currently, as the Chief Scientific Officer (CSO) at TAXIS, he oversees all drug discovery programs.

His extensive expertise encompasses synthetic medicinal chemistry and microbiology, coupled with a deep understanding of pharmacology and toxicology. Dr. Parhi’s adeptness in managing multi-million-dollar grants and his experience in collaborative, matrix-based environments position him as an exceptional leader to drive research and development at TAXIS.

An accomplished researcher, Dr. Parhi has authored and co-authored 40 peer-reviewed publications and is a co-inventor on over 30 patent applications. He has also received two prestigious federal grants from CARB-X and NIAID as principal investigator.

Dr. Parhi earned his Ph.D. from the City University of New York and completed his postdoctoral research at the University of Pennsylvania.

greg mario

Gregory G. Mario

MBA, President and CEO

Mr. Mario joins TAXIS with more than 20 years of experience in the life sciences industry as a sales, marketing, business development, and licensing and acquisition professional. Prior to his role at TAXIS, he served as the Senior VP of Business Development with Talk America, a local-long distance telecommunications provider, and remains Partner at MFP, LP, a private equity investment entity focused on the life sciences sector. Mr. Mario co-founded the Brownstone Advisory Group, a real estate investment fund, and is a Director at Evogen, Inc., a development stage laboratory diagnostics company focused on central nervous system disease management.

Mr. Mario received a B.S. in Biochemistry from Trinity College. He earned an M.B.A. in Finance and Marketing at the Fuqua School of Business, Duke University as a Fuqua Scholar.

Go to Top